Top 10 Insider Purchases Last Month

4. Sionna Therapeutics, Inc. (NASDAQ:SION)

Total value of insider purchases in February: $62,460,000.00

Market capitalization: $730.22 million

A biopharmaceutical company, Sionna Therapeutics, is also among the 10 stocks insiders are buying this year. The Waltham, Massachusetts-headquartered company is engaged in the development of new treatments for cystic fibrosis (CF). Its founders have more than a decade of research in the area and are leading the company to develop new therapeutics that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients.

Sionna went public in February, and six insiders decided to take part in the offering by buying a total of around $62.46 million worth of Sionna shares at a price of $18 per share. Since its IPO, Sionna stock lost 33.60% and is now trading at $16.60 per share.

Three analysts have given an average “Buy” rating to Sionna stock, with a 12-month price target of $38.50, according to MarketBeat. The average price target suggests a potential upside of 132.91% from the latest price.